Christian Buchold
Darmstadt, HE 64293, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease.
Journal: Cells
Published: March 31, 2022
Clinical Validation of an Automated Fluorogenic Factor XIII Activity Assay Based on Isopeptidase Activity.
Journal: International journal of molecular sciences
Published: December 22, 2020
Feasibility of an automated coagulation factor XIIIa test using its isopeptidase activity.
Journal: Analytical biochemistry
Published: January 20, 2020
Novel inhibitor ZED3197 as potential drug candidate in anticoagulation targeting coagulation FXIIIa (F13a).
Journal: Journal of thrombosis and haemostasis : JTH
Published: June 19, 2019
Development of fluorine-18 labeled peptidic PET tracers for imaging active tissue transglutaminase.
Journal: Nuclear medicine and biology
Published: August 05, 2016
Structure of active coagulation factor XIII triggered by calcium binding: basis for the design of next-generation anticoagulants.
Journal: Angewandte Chemie (International ed. in English)
Published: June 14, 2013
Differences in the inhibition of coagulation factor XIII-A from animal species revealed by Michael Acceptor- and thioimidazol based blockers.
Journal: Thrombosis research
Published: November 19, 2012
Showing 1-8 of 8
Last Updated: 09/26/2026